Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2007

View Archived Issues

Novel treatment for dermatological disorders reported in recent Galderma patent

TRPM8: novel prognostic marker and potential therapeutic target in prostate cancer

Helioxanthin analogue shows a distinctive mechanism of action against HBV infection

Cardiome Pharma updates Q1 highlights

Ono reports events of fourth quarter

New vaccine developments reported

Recent Abbott and Organon patents report novel analgesic agents

Biolipox patents novel 15-lipoxygenase inhibitors

Snapshots on biological psychiatry

New drug-eluting stent data presented

NT69L and LY-379268 studied for possible use in nicotine addiction

Vical reports findings on Vaxfectin-formulated DNA vaccine

CEL-100 enhances immune response against H5 antigen in animals

VGX's HIV and avian flu vaccines trigger immune responses in preclinical studies

Subgroup analysis of diabetic patients receiving Cypher stent

Medtronic reports new data for Endeavor and Endeavor Resolute stents

Oritavancin shows potential as a treatment for anthrax exposure

Positive interim results for DNA-based immunotherapy delivered by electroporation

CV Therapeutics reduces operating expenses

Japanese approval for new higher dosage of Magnevist

Canadian approval for Cangene's VIG

Preclinical data reported for HDAC inhibitor MGCD-290

MedImmune receives FDA correspondence regarding FluMist sBLA

Interim phase I results for Iomai's patch vaccine for seasonal influenza

Tindamax approved for bacterial vaginosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...